Publications & Posters

Peer-Reviewed Work & Conference Presentations

Publications

Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemia
November 2025 — Blood, Volume 146, Issue 21
Targetable BIRC5 dependency in therapy-resistant TP53 mutated acute myeloid leukemia
May 2025 — bioRxiv (Preprint)
Somatic TP53 Mutations Drive T and NK Cell Dysfunction in AML and Can be Rescued by Reactivating Wild Type p53
April 2025 — medRxiv (Preprint)
BKT300: A Novel Anti-Leukemic Small Molecule Targeting the Protein Regulator of Cytokinesis 1 (PRC1) Pathway
February 2025 — Research Square (Preprint)
Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia
April 2024 — Leukemia, Volume 38, pp. 729–740
Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022
March 2024 — Blood, Volume 143, Issue 12
Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias
December 2023 — Science Advances
Mdm2/p53 levels in bone marrow mesenchymal stromal cells are essential for maintaining the hematopoietic niche in response to DNA damage
June 2023 — Cell Death & Disease
Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics
April 2023 — Blood Cancer Journal
3q26.2/MECOM Rearrangements by Pericentric Inv(3): Diagnostic Challenges and Clinicopathologic Features
January 2023 — Cancers
Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment
September 2022 — Leukemia & Lymphoma
Mds1CreERT2, an inducible Cre allele specific to adult-repopulating hematopoietic stem cells
August 2021 — Cell Reports
EVI1 overexpression reprograms hematopoiesis via upregulation of Spi1 transcription
October 2018 — Nature Communications

First author. The University of Rochester Medical Center acknowledged this publication in the departmental news.

Recessive and Dominant De Novo ITPR1 Mutations Cause Gillespie Syndrome
May 2016 — American Journal of Human Genetics

Conference Presentations

Single-Cell Multiomics Unveils Venetoclax-Resistant Monocytic Differentiation and Immune Evasion in TP53 Mutant AML Clones
December 2024 — 66th ASH Annual Meeting & Exposition (Oral Presentation)

Highlighted as one of the "Select Abstracts of Key Advances in AML" by The Practical Hematologist.

Single-Cell Genomics and Proteomics Reveals Venetoclax-Resistant Monocytic Differentiation of TP53 LOH Clones in TP53 Mutant AML
December 2023 — 65th ASH Annual Meeting & Exposition
Polyploidy Is Necessary for Apoptotic Cell Death in TP53-Mut AML in Response to PLK4 Inhibition and Results in Caspase 3 Cleavage
November 2022 — 64th ASH Annual Meeting & Exposition
Targeting Polo-like Kinase 4 Triggers Polyploidy and Apoptotic Cell Death in TP53-Mutant Acute Myeloid Leukemia
December 2021 — 63rd ASH Annual Meeting & Exposition

This abstract received the ASH Abstract Achievement Award, a merit-based award for trainees who are the first author and presenter on a high-scoring annual meeting abstract.

MDS1-EVI1 Complex (MECOM) Activation Promotes Leukemic Stem Cell Quiescence By Upregulating CDKN1C/P57Kip2
December 2020 — 62nd ASH Annual Meeting & Exposition

This abstract received the ASH Abstract Achievement Award, a merit-based award for trainees who are the first author and presenter on a high-scoring annual meeting abstract.

EVI1 overexpression reprograms hematopoiesis via upregulation of Spi1 transcription
April 2019 — Gordon Research Conference - Cancer Genetics and Epigenetics
EVI1 overexpression reprograms hematopoiesis via upregulation of Spi1 transcription
November 2018 — James Wilmot Cancer Institute 23rd Annual Scientific Symposium
Role of the Oncogene EVI1 in Leukemia-Associated Anemia
May 2018 — The Patricia Hinkle Symposium, University of Rochester
Role of the Oncogene EVI1 in Leukemia-Associated Anemia
February 2018 — University of Rochester Research Poster Session
EVI1 Expands Myelopoiesis via Upregulation of Spi1 Transcription
November 2017 — James Wilmot Cancer Institute 22nd Annual Scientific Symposium
High-Level EVI1 Reprograms Hematopoietic Differentiation
October 2017 — European School of Hematology 4th International Conference on AML
High-Level EVI1 Reprograms Hematopoietic Differentiation
May 2017 — University of Rochester Graduate Student Society Poster Session
EVI1 Expands Myelopoiesis via Upregulation of Spi1 Transcription
November 2016 — James Wilmot Cancer Institute 21st Annual Scientific Symposium